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Leading article
Why is epidermal growth factor present in the gut lumen?
Epidermal growth factor (EGF) is a potent mitogen which
is continuously secreted into the gut lumen. The sequence
and structure of EGF and its receptor have been known
for many years. In addition, numerous studies have been
performed which are starting to unravel the events which
occur after EGF meets its receptor. Despite the great
number of papers that have been published in this field,
the physiological role of luminal EGF is still unclear. Why
is this? In this article we discuss the various methods
which have been used to examine the function of EGF in
vitro and in vivo and discuss the limitations of these
approaches. We also discuss the potential value ofEGF as
a therapeutic target for the treatment of human gastro-
intestinal disease.
Background to EGF and its receptor
EGF is a 53 amino acid peptide (MW 6400) which is
secreted into the gut lumen by the salivary glands,
Brunner's glands of the duodenum, and also by the ulcer
associated cell lineage (UACL) - a recently identified glan-
dular structure induced at sites of injury.1 2 Its concentra-
tion in gastric juice is about 500 ng/l, while urine
concentrations are about one tenth of this.3 4 Circulating
concentrations ofEGF are extremely low and much of this
circulating EGF is bound to platelets. The human EGF
receptor has been cloned and is a 170 kDa protein that
consists of a cell surface ligand binding domain, a single
hydrophobic transmembrane domain, and a cytoplasmic
tyrosine kinase domain. When EGF binds to its receptor it
results in clustering, dimerisation, and internalisation of
the receptor-ligand complex. Although this protein is
called the EGF receptor, it is important to note that it also
binds transforming growth factor oa, amphiregulin, and
heparin binding EGF. The relative physiological impor-
tance of these different ligands is unclear. This article
focuses predominantly on EGF. An excellent detailed
review of EGF related peptides has been published by
Barnard et al.5
Actions ofEGF
EGF is a potent stimulant of proliferation for a variety of
cell lines in vitro. In addition, many studies have shown
that systemic administration of EGF results in acid sup-
pression and cytoprotective action against a variety of acid
dependent and independent models of gastric ulceration.
Because most of the EGF is present in the lumen and
circulating concentrations are low, however, it is probable
that any major physiological role of EGF will be mediated
via luminal EGF and not via the systemic circulation. Four
main approaches have been used to examine the function
of luminal EGF:
INTRALUMINAL ADMINISTRATION OF EGF
Studies in which EGF has been administered intra-
luminally initially seem to be the most appropriate. Most
of these have been performed using rats, and there is a
consensus developing that luminal EGF is active in
stimulating gut growth in the neonatal rat and also in the
damaged bowel. Whether administration of luminal EGF
to the undamaged bowel stimulates growth, however, is
uncertain. The reasons for the apparently conflicting
results are unclear but differences in dosage used, species
studied, and bolus versus continuous infusion ofEGF may
all be important. Equivalent studies in humans have not
been performed. When interpreting the results of studies
examining the effect of luminally administered EGF, it is
important that the details of the experimental protocol are
considered. For example, studies examining the effect of
luminal EGF on intestinal growth in intestine that has
recently undergone resection may be influenced by the
increased gut permeability caused by surgical handling
and the presence of an anastomosis. Caution has to be
shown in interpreting these results in terms of 'normal'
physiology.
The importance of considering the experimental design
is shown by our studies on the stability of growth factors in
the gastrointestinal lumen. We have shown that luminal
EGF is susceptible to proteolytic digestion in the stomach
(by pepsin) but that this is reduced considerably if the pH
is raised above 4.3 Protocols involving administration of
acid suppressants may therefore result in an appreciable
change in luminal EGF bioactivity.
Differences in the diet of the animals may also be impor-
tant as we have shown that EGF is also susceptible to
degradation by pancreatic proteases present in the small
intestine.6 Luminal EGF is rapidly destroyed in the small
intestine of fasted, but not fed, rats. This is probably
because the food proteins (in the fed rats) act as competi-
tive substrates for the luminal proteases and the digestion
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of luminal EGF is therefore decreased. Concentrations of
endogenous and exogenously administered EGF will
therefore vary according to whether the animals are fasted
or fed and the type of diet used. We reported that systemic,
but not luminal EGF, was trophic to the intestine of
parenterally fed rats7 and this is often quoted as a key
paper showing the lack of effect of luminal EGF. However,
we have subsequently shown that the intraluminally
infused EGF was rapidly digested by residual proteases
and was therefore not available to stimulate growth. We
have also shown that if EGF is co-infused with soya bean
trypsin inhibitor (to reduce luminal degradation of the
EGF) it does stimulate growth of the small intestine.8
However, when interpreting our latest results it emerges
that parenterally fed animals probably have increased gut
permeability which might allow EGF to reach its receptor,
even if the EGF receptor is not present on the apical
membranes (see later). These types of experiments should
be interpreted with caution!
EXAMINATION OF THE DISTRIBUTION OF THE
EGF/RECEPTOR
If luminal EGF is important in maintaining gut growth,
one would expect the receptor to be present on the apical
(luminal) membranes. Various techniques have been used
to examine this question, including immunocytochemistry,
Western blotting of microvillus preparations, and auto-
radiography. Most of these studies have examined the dis-
tribution of the EGF receptor in animal models, especially
the rat. A recent paper by Thompson et al 9 reported that in
the adult and neonatal rat, the EGF receptor is restricted
to the basolateral membranes. This suggests that the
reason luminal EGF is active in rat neonatal gut is because
the increased permeability of the neonatal bowel allows
passage of luminal EGF to its receptor on the basolateral
membranes. This is an important result as most studies
have been performed under the assumption that the distri-
bution of the EGF receptor might alter as the rat matures.
In contrast to these findings, studies using autoradi-
ographic localisation of the EGF receptor in the pig intes-
tine suggests an apical (luminal) distribution.10 If EGF
receptors are present on the apical membranes, they prob-
ably only constitute a small proportion of the number seen
on the basolateral membranes. Particular care must be
taken to prevent false negative results due to insufficient
sensitivity, and conversely, that contamination of apical
membrane preparations with relatively small amounts of
basolateral membranes does not produce false positive
results. Our recent studies examining the distribution of
the EGF receptor in the human gastrointestinal tract
(using immunohistochemistry, electron microscopy, and
Western blotting techniques) suggest that in the human
adult the receptor is restricted to the basolateral mem-
branes.11 Preliminary immunolocalisation studies suggest
that the distribution may be different in the damaged
human bowel.12
EXAMINATION OF THE EFFECT OF REDUCING
INTRALUMINAL EGF CONCENTRATIONS BY REMOVAL OF
THE SALIVARY GLANDS
Removal of the salivary glands of rats markedly reduces the
concentrations ofEGF present in gastric juice. Despite this
reduction, gastric acid secretion does not rise and spon-
taneous ulceration does not occur.13 However, several
studies suggest that gastric mucosal growth is reduced by
this procedure (for example, ref'4) although the small
intestine and colon are probably not affected.14 15
However, to complicate matters further, Li and co-workers
have reported that removal of salivary glands does not
cause intestinal atrophy but, somewhat confusingly, that
artificially induced salivary hypersecretion stimulates small
intestinal growth. 15 In contrast to the relatively small effect
that sialadenectomy has on the non-damaged bowel, there
is a general consensus that artificially-induced ulcers are
more extensive and take longer to heal in rats which have
undergone sialadenectomy (for example, ref13). Caution is
needed before extrapolating these results to humans,
although patients with gastric ulceration do have reduced
levels of gastric juice EGF.16
PRODUCTION OF KNOCK OUT MICE
Rapid advances in molecular biological techniques now
allow animal models to be produced in which a particular
gene ofinterest is disrupted (or knocked out) in every cell of
the body. These animals are then examined to predict the
function of the targeted gene. Initially it was assumed that
the development of an EGF receptor 'knock out' mouse
model would make a major contribution to establishing the
function ofEGF in vivo. This model has recently been pro-
duced but, in at least one strain, the animals die within a
few days of birth due to respiratory disease and intestinal
ulceration. 17 While this result emphasises the importance of
the EGF receptor, it does not allow us to define the role of
EGF, which is only one of the many ligands binding to this
receptor. Other groups have developed their own EGF
receptor knockout mice (using different mice strains) but in
contrast to the findings of Miettinenpj et al, these animals
do not get severe colitis.'8 19 These findings emphasise the
need to show caution in extrapolating results from mice to
humans. To determine which of the EGF receptor ligands
are physiologically important, each needs to be individually
'knocked out'. Transforming growth factor a knockout
mice have already been produced and the gastrointestinal
tract seems normal.20 The production of EGF knock out
mice is awaited with interest.
Possible clinical value ofrecombinant EGF
Taken together, the studies performed so far suggest that
the major role of EGF is to stimulate repair at sites of
injury and that it plays a relatively minor role in the main-
tenance of normal gut growth in the human adult.
However, administration of recombinant EGF via the
lumen may be clinically useful for the treatment of gastro-
intestinal ulceration distal to the duodenum. Acid
suppressants and Helicobacterpylori eradication therapy are
very effective treatments for peptic ulceration. However,
the treatment of inflammatory bowel disease, chemother-
apy induced mucositis, and necrotising enterocolitis is still
suboptimal. Preliminary studies suggest that recombinant
EGF may be useful in the treatment of all these condi-
tions.21 Although nearly all studies have examined the
effect of systemic EGF on these conditions, treatment with
luminal EGF may well provide a safer alternative as the
bowel is damaged (with increased permeability) and
luminal EGF is therefore likely to reach its receptor. If
clinical trials examining the potential value ofluminal EGF
are to be performed, co-administration of acid suppres-
sants (to reduce gastric digestion), protease inhibitors (to
reduce proteolysis by pancreatic proteases), or trefoil
peptides (which act synergistically with EGF in the healing
process,22 may well improve its clinical effectiveness.
Conclusions
The jury is still out on the role of luminal EGF in the
normal gastrointestinal tract. Recent evidence, however,
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suggests that its major function is to act as a 'luminal sur-
veillance' peptide,23 which is available to stimulate repair
and that it is not of major importance in maintaining
normal gut growth. Recombinant EGF administered via
the gut lumen could still prove a valuable tool for the treat-
ment of gastrointestinal ulceration. Perhaps the old term
for EGF, 'epidermal healing factor' or EHF, was more
appropriate after all!
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